Chemotherapy in the management of advanced cutaneous malignant melanoma.
Chemotherapy in the management of advanced cutaneous malignant melanoma.
复制标题
DOI：
10.1016/j.clindermatol.2012.08.016
复制
发表时间：
2013-05
影响因子：
2.7
通讯作者：
Schwartz GK
中科院分区：
文献类型：
--
作者：
Luke JJ;Schwartz GK
最近，通过在约50%的患者中靶向突变BRAF和在所有患者中阻断免疫检查点，在治疗晚期恶性黑色素瘤方面取得了前所未有的临床进展。然而，正如已经充分证明的那样，对靶向治疗的反应是有限的，并且免疫治疗的临床获益率是适度的。考虑到这些因素，化疗患者的缓解仍然是黑色素瘤肿瘤学的一个重要方面。已经在黑色素瘤中评价了许多化疗药物（以及与其他药物如免疫疗法的组合），但在前瞻性、随机化、良好对照的III期研究中，没有记录到化疗方案可提供总生存期获益。在这里，我们概述了黑色素瘤最常见的化疗方案的发展，讨论了支持和对比它们的临床试验证据，并强调了它们可能被采用的适当临床情况。最后，我们讨论了黑色素瘤化疗的未来，注意到化疗与靶向或免疫抑制剂组合的潜力。
The recent past has witnessed unprecedented clinical progress in the treatment of advanced malignant melanoma through targeting of mutant BRAF in approximately 50 percent of patients and immune check point blockade in all patients. As has been well documented however, responses to targeted therapy are of limited duration and rates of clinical benefit to immunotherapy are modest. Given these factors, palliation of patients with chemotherapy remains an essential aspect of melanoma oncology. Many chemotherapeutics (and combinations with other agents such as immunotherapy) have been evaluated in melanoma however no chemotherapy regimen has been documented to provide an overall survival benefit in a prospective, randomized, well controlled phase III study. Here, we overview the development of the most common chemotherapy regimens for melanoma, discuss the clinical trial evidence supporting and contrasting them and highlight appropriate clinical situations in which they might be employed. Finally, we discuss the future of chemotherapy for melanoma, noting the potential for combinations of chemotherapy with either targeted or immunotherapeutic agents.
登录
查看更多内容
通过淋巴结消除来清除稳态细胞因子下沉，增强了采用转移的肿瘤特异性CD8+ T细胞的功效。
影响因子：
15.3
作者：
Gattinoni, Luca;Finkelstein, Steven E;Klebanoff, Christopher A;Antony, Paul A;Palmer, Douglas C;Spiess, Paul J;Hwang, Leroy N;Yu, Zhiya;Wrzesinski, Claudia;Heimann, David M;Surh, Charles D;Rosenberg, Steven A;Restifo, Nicholas P
通讯作者：
Restifo, Nicholas P
影响因子：
45.3
作者：
Atkins, Michael B.;Hsu, Jessie;Kirkwood, John M.
通讯作者：
Kirkwood, John M.
影响因子：
45.3
作者：
Creagan, ET;Suman, VJ;Michalak, JC
通讯作者：
Michalak, JC
影响因子：
8.4
作者：
AAMDAL, S;WOLFF, I;VERWEIJ, J
通讯作者：
VERWEIJ, J
影响因子：
45.3
作者：
Chapman, PB;Einhorn, LH;Kirkwood, JM
通讯作者：
Kirkwood, JM